

Pier Luigi Zinzani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3406813/publications.pdf>

Version: 2024-02-01

679
papers

41,038
citations

2538

96
h-index

3476

182
g-index

702
all docs

702
docs citations

702
times ranked

21332
citing authors

#	ARTICLE	IF	CITATIONS
1	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. <i>Lancet Oncology</i> , The, 2006, 7, 379-391.	5.1	1,840
2	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2010, 376, 1164-1174.	6.3	1,713
3	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	0.6	1,552
4	PI3K γ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	13.9	956
5	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2125-2132.	0.8	830
6	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1283-1294.	5.1	818
7	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. <i>Lancet Oncology</i> , The, 2011, 12, 1013-1022.	5.1	633
8	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.	0.8	586
9	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. <i>Leukemia</i> , 2007, 21, 340-350.	3.3	571
10	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
11	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	0.8	551
12	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1182-1189.	0.8	535
13	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	6.3	517
14	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
15	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003, 101, 2489-2495.	0.6	494
16	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , The, 2017, 390, 555-566.	6.3	444
17	Phase III Trial of Consolidation Therapy With Yttrium-90 ⁹⁰ Y-ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5156-5164.	0.8	431
18	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	5.1	398

#	ARTICLE	IF	CITATIONS
19	T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. <i>Gastroenterology</i> , 2002, 122, 1286-1294.	0.6	397
20	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	0.8	388
21	ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned. <i>New England Journal of Medicine</i> , 2011, 365, 203-212.	13.9	379
22	An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2011, 22, 1622-1627.	0.6	361
23	Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. <i>Journal of Clinical Oncology</i> , 2006, 24, 2472-2479.	0.8	354
24	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2018, 391, 659-667.	6.3	324
25	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3898-3905.	0.8	320
26	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	13.9	281
27	Peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 6756-6767.	0.6	278
28	Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. <i>Cancer</i> , 2011, 117, 5058-5066.	2.0	277
29	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	0.8	273
30	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. <i>Journal of Clinical Investigation</i> , 2007, 117, 823-834.	3.9	272
31	Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4293-4297.	0.8	268
32	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013, 24, 857-877.	0.6	268
33	Nongastrointestinal Low-Grade Mucosa-Associated Lymphoid Tissue Lymphoma: Analysis of 75 Patients. <i>Journal of Clinical Oncology</i> , 1999, 17, 1254-1254.	0.8	264
34	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2017, 130, 267-270.	0.6	255
35	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.	0.6	255
36	Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2197-2203.	0.8	251

#	ARTICLE	IF	CITATIONS
37	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	0.6	249
38	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018, 132, 2115-2124.	0.6	232
39	Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 2603-2606.	0.8	220
40	Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation. <i>Cancer Research</i> , 2007, 67, 10703-10710.	0.4	220
41	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 790-800.	5.1	211
42	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
43	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2169-2178.	0.6	207
44	DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 912-922.	0.8	201
45	Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 1376-1382.	0.8	199
46	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
47	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	0.8	195
48	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
49	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. <i>Lancet Oncology</i> , The, 2008, 9, 435-444.	5.1	190
50	Hodgkin's lymphoma: the pathologist's viewpoint. <i>Journal of Clinical Pathology</i> , 2002, 55, 162-176.	1.0	189
51	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.	3.3	184
52	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , the, 2019, 6, e254-e265.	2.2	184
53	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2022, 28, 325-332.	15.2	182
54	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi149-vi154.	0.6	175

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. <i>Blood</i> , 2007, 110, 54-58.	0.6	171
56	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv30-iv40.	0.6	171
57	Treatment and Clinical Management of Primary Mediastinal Large B-Cell Lymphoma With Sclerosis: MACOP-B Regimen and Mediastinal Radiotherapy Monitored by 67Gallium Scan in 50 Patients. <i>Blood</i> , 1999, 94, 3289-3293.	0.6	167
58	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 730-737.	5.1	164
59	Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. <i>Annals of Oncology</i> , 2010, 21, 860-863.	0.6	162
60	Primary Mediastinal B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2003, 162, 243-253.	1.9	160
61	Role of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1781-1787.	0.8	160
62	The role of positron emission tomography (PET) in the management of lymphoma patients. <i>Annals of Oncology</i> , 1999, 10, 1181-1184.	0.6	156
63	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002, 99, 856-862.	0.6	155
64	Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. <i>Cancer</i> , 2005, 104, 2437-2441.	2.0	149
65	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	0.8	149
66	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 ⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	0.8	149
67	Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3880-3886.	0.8	148
68	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 512-524.	5.1	144
69	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002, 87, 1258-64.	1.7	141
70	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
71	Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. <i>Annals of Oncology</i> , 2006, 17, 1296-1300.	0.6	137
72	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4127-4137.	3.2	135

#	ARTICLE	IF	CITATIONS
73	Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 2654-2661.	0.8	130
74	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3019-3025.	0.8	129
75	Interim Positron Emission Tomography Response—Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1376-1385.	0.8	128
76	The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.4	127
77	Consensus conference on the management of tumor lysis syndrome. <i>Haematologica</i> , 2008, 93, 1877-1885.	1.7	125
78	Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1997, 8, 583-592.	0.6	124
79	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124
80	High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.. <i>Journal of Clinical Oncology</i> , 1996, 14, 534-542.	0.8	122
81	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3081-3089.	0.8	120
82	Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 4-12.	3.3	119
83	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020, 7, e112-e121.	2.2	119
84	Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin's Lymphoma: An Italian Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 1255-1262.	0.8	117
85	CD30 expression in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, e81-e82.	1.7	117
86	PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). <i>Blood</i> , 2014, 124, 290-290.	0.6	112
87	Umbralisib, a Dual PI3K/CK1 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	0.8	111
88	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , 2012, 13, 696-706.	5.1	109
89	Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. <i>Annals of Oncology</i> , 1998, 9, 1351-1353.	0.6	106
90	Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 462-466.	0.2	106

#	ARTICLE	IF	CITATIONS
91	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	0.6	106
92	Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides. <i>Cancer</i> , 2012, 118, 5830-5839.	2.0	105
93	Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. <i>Annals of Oncology</i> , 2013, 24, 2892-2897.	0.6	105
94	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	2.0	104
95	Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. <i>Blood</i> , 2005, 105, 3428-3433.	0.6	102
96	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. <i>American Journal of Hematology</i> , 2020, 95, 362-371.	2.0	102
97	Consensus-based definition of unfit to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. <i>Leukemia</i> , 2013, 27, 997-999.	3.3	101
98	Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases. <i>British Journal of Haematology</i> , 1994, 86, 513-523.	1.2	100
99	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008, 112, 325-325.	0.6	99
100	The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2022, 33, 288-298.	0.6	99
101	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 773-784.	5.1	98
102	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
103	Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. <i>Cancer</i> , 2012, 118, 434-443.	2.0	97
104	Peripheral T-cell lymphoma " Not otherwise specified. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 321-329.	2.0	95
105	Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. <i>British Journal of Cancer</i> , 2004, 91, 850-854.	2.9	94
106	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , 2012, 97, 1085-1091.	1.7	94
107	Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 613-623.	0.8	91
108	Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.. <i>Journal of Clinical Oncology</i> , 1996, 14, 955-962.	0.8	90

#	ARTICLE	IF	CITATIONS
109	Myeloperoxidase Expression by Histiocytes in Kikuchi's and Kikuchi-Like Lymphadenopathy. American Journal of Pathology, 2001, 159, 915-924.	1.9	90
110	Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Annals of Oncology, 2009, 20, 1993-1999.	0.6	90
111	Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma. Journal of Clinical Oncology, 2000, 18, 773-773.	0.8	89
112	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Annals of Oncology, 2018, 29, 2363-2370.	0.6	89
113	Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nuclear Medicine Communications, 2005, 26, 689-694.	0.5	88
114	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	0.6	86
115	Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Annals of Oncology, 1993, 4, 575-578.	0.6	84
116	Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer, 2004, 100, 2190-2194.	2.0	84
117	Enteropathy-associated T-cell lymphoma. Critical Reviews in Oncology/Hematology, 2011, 79, 84-90.	2.0	83
118	In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma. Journal of Clinical Oncology, 2014, 32, 2705-2711.	0.8	83
119	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 678-689.	5.1	83
120	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematology, the, 2021, 8, e410-e421.	2.2	83
121	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 2482-2494.	13.9	83
122	Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2007, 48, 708-715.	0.6	81
123	Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v100-v107.	0.6	81
124	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncology, The, 2008, 9, 352-358.	5.1	80
125	Peripheral T-cell lymphoma, not otherwise specified. Blood, 2017, 129, 1103-1112.	0.6	79
126	Primary bone lymphoma: experience with 52 patients. Haematologica, 2003, 88, 280-5.	1.7	78

#	ARTICLE	IF	CITATIONS
127	Isolated Central Nervous System Relapse in Aggressive Non-Hodgkin's Lymphoma: the Bologna Experience. <i>Leukemia and Lymphoma</i> , 1999, 32, 571-576.	0.6	76
128	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. <i>Histopathology</i> , 2002, 41, 482-509.	1.6	75
129	Mycosis fungoides. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 172-182.	2.0	75
130	Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. <i>Haematologica</i> , 2007, 92, 771-777.	1.7	74
131	Peripheral T cell lymphomas: from the bench to the clinic. <i>Nature Reviews Cancer</i> , 2020, 20, 323-342.	12.8	74
132	Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. <i>Haematologica</i> , 2008, 93, 1033-1038.	1.7	73
133	Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. <i>Haematologica</i> , 2005, 90, 702-3.	1.7	73
134	Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease.. <i>Journal of Clinical Oncology</i> , 1993, 11, 925-930.	0.8	72
135	A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. <i>Annals of Oncology</i> , 2008, 19, 769-773.	0.6	72
136	Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. <i>Blood</i> , 2017, 129, 2328-2330.	0.6	72
137	Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 381-385.	1.4	70
138	Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <i>In vitro</i> and <i>In vivo</i> Models of T-Cell Lymphoid Malignancies. <i>Clinical Cancer Research</i> , 2010, 16, 3648-3658.	3.2	70
139	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. <i>Leukemia and Lymphoma</i> , 2016, 57, 766-782.	0.6	70
140	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2021, 384, 1810-1823.	13.9	70
141	The many faces of marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 426-432.	0.9	69
142	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	1.7	68
143	Activity of Oral Fludarabine Phosphate in Previously Treated Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 4252-4258.	0.8	67
144	Extranodal Marginal Zone B-cell Lymphoma of MALT-type of the Lung: Single-center Experience with 12 Patients. <i>Leukemia and Lymphoma</i> , 2003, 44, 821-824.	0.6	67

#	ARTICLE	IF	CITATIONS
145	Expression of CD52 in peripheral T-cell lymphoma. <i>Haematologica</i> , 2007, 92, 566-567.	1.7	67
146	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67
147	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019, 33, 2762-2766.	3.3	67
148	Primary non-hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 760-764.	0.4	66
149	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 113, 2496-2503.	2.0	66
150	Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. <i>British Journal of Haematology</i> , 1995, 89, 780-789.	1.2	66
151	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 1364-1371.	1.7	66
152	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. <i>Haematologica</i> , 2009, 94, 550-565.	1.7	66
153	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
154	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011, 22, 689-695.	0.6	64
155	Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. <i>Journal of Clinical Pathology</i> , 2008, 61, 1160-1167.	1.0	63
156	Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1936-1944.	2.8	63
157	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016, 3, e467-e479.	2.2	63
158	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018, 132, 179-186.	0.6	63
159	18F-FDG PET in malignant lymphoma: significance of positive findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 749-756.	3.3	62
160	Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. <i>Haematologica</i> , 2005, 90, 225-31.	1.7	62
161	Fludarabine treatment in resistant Waldenstrom's macroglobulinemia. <i>European Journal of Haematology</i> , 1995, 54, 120-123.	1.1	60
162	Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3998-4004.	3.2	60

#	ARTICLE	IF	CITATIONS
163	Midtreatment ¹⁸ F-fluorodeoxyglucose positron emission tomography in aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 1010-1018.	2.0	60
164	Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?. <i>British Journal of Haematology</i> , 1991, 79, 48-51.	1.2	59
165	Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. <i>Hematological Oncology</i> , 2019, 37, 3-14.	0.8	59
166	Expression of platelet-derived growth factor receptor $\hat{\pm}$ in peripheral T-cell lymphoma not otherwise specified. <i>Lancet Oncology</i> , The, 2005, 6, 440.	5.1	58
167	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1080-1088.	3.4	58
168	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 6553-6569.	0.8	58
169	Pathobiology of Primary Mediastinal B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S21-S26.	0.6	57
170	Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. <i>Leukemia</i> , 2012, 26, 499-508.	3.3	57
171	Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. <i>Haematologica</i> , 2004, 89, 309-13.	1.7	57
172	Phase multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB $\hat{\pm}$ IVA mycosis fungoides/SÅzary syndrome. <i>British Journal of Dermatology</i> , 2016, 175, 80-88.	1.4	56
173	The landscape of new drugs in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 335-346.	12.5	56
174	Adult Lymphoblastic Lymphoma: Clinical Features and Prognostic Factors in 53 Patients. <i>Leukemia and Lymphoma</i> , 1996, 23, 577-582.	0.6	55
175	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
176	Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1532-1537.	0.8	54
177	The Role of Mitoxantrone in the Treatment of Indolent Lymphomas. <i>Oncologist</i> , 2005, 10, 150-159.	1.9	54
178	18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2096-2101.	0.6	54
179	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. <i>Blood Cancer Journal</i> , 2014, 4, e236-e236.	2.8	54
180	The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 215-226.	1.2	51

#	ARTICLE	IF	CITATIONS
181	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 35.	6.9	51
182	Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. <i>Journal of Clinical Pathology</i> , 2002, 55, 684-688.	1.0	50
183	The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. <i>Leukemia</i> , 2004, 18, 1215-1222.	3.3	49
184	Rituximab in primary conjunctiva lymphoma. <i>Leukemia Research</i> , 2005, 29, 107-108.	0.4	49
185	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM</sc> PET) of standard therapy on treatment outcome in early stage <sc>H</sc> odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
186	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
187	Hairy cell leukemia. <i>Cancer</i> , 2010, 116, 4788-4792.	2.0	48
188	Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2011, 52, 1585-1588.	0.6	48
189	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT). <i>Oncology</i> , 2016, 34, 177-183.	0.8	48
190	Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. <i>Cancer</i> , 1994, 74, 1792-1800.	2.0	47
191	Comparison of prognostic models in patients with advanced Hodgkin disease. <i>Cancer</i> , 2001, 91, 1467-1478.	2.0	47
192	The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. <i>Cancer</i> , 2004, 101, 1824-1834.	2.0	47
193	Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1997, 8, 379-383.	0.6	46
194	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	2.5	46
195	Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1994, 88, 770-777.	1.2	45
196	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
197	Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: Clinical and therapeutic features of 24 localized patients. <i>Annals of Oncology</i> , 1997, 8, 883-886.	0.6	44
198	Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 291-295.	1.4	44

#	ARTICLE	IF	CITATIONS
199	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium ⁹⁰ ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 112, 856-862.	2.0	43
200	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , 2005, 90, 341-7.	1.7	43
201	Lymphoproliferative Lung Disorders. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 490-501.	0.8	42
202	The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. <i>British Journal of Haematology</i> , 2011, 154, 477-481.	1.2	42
203	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	3.2	42
204	The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1715-1722.	1.9	41
205	Clinical implications of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1995, 54, 9-17.	1.1	41
206	Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. <i>Leukemia</i> , 1997, 11, 629-632.	3.3	39
207	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the international E-xtranodal Lymphoma Study Group. <i>British Journal of Haematology</i> , 2014, 166, 69-76.	1.2	39
208	Pyothorax-associated lymphoma: Description of the first two cases detected in Italy. <i>Annals of Oncology</i> , 1997, 8, 1133-1138.	0.6	38
209	MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. <i>Annals of Oncology</i> , 2010, 21, 1173-1178.	0.6	38
210	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016, 101, e407-e410.	1.7	38
211	Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. <i>Cancer Treatment Reviews</i> , 2017, 60, 120-129.	3.4	38
212	KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. <i>Blood Advances</i> , 2020, 4, 2617-2622.	2.5	38
213	T-Cell Lymphomas in South America and Europe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 42-47.	0.7	38
214	Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. <i>American Journal of Hematology</i> , 1994, 47, 301-306.	2.0	37
215	Expression of B-Lymphocyte-Associated Transcription Factors in Human T-Cell Neoplasms. <i>American Journal of Pathology</i> , 2003, 162, 861-871.	1.9	37
216	Lymphoma: Diagnosis, staging, natural history, and treatment strategies. <i>Seminars in Oncology</i> , 2005, 32, 4-10.	0.8	37

#	ARTICLE	IF	CITATIONS
217	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1013-1022.	0.8	36
218	Advantages of Positron Emission Tomography (PET) with Respect to Computed Tomography in the Follow-up of Lymphoma Patients with Abdominal Presentation. <i>Leukemia and Lymphoma</i> , 2002, 43, 1239-1243.	0.6	35
219	Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 162, 639-647.	1.2	35
220	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 3606-3610.	2.5	35
221	Primary Mediastinal B-Cell Lymphoma with Sclerosis: Clinical and Therapeutic Evaluation of 22 Patients. <i>Leukemia and Lymphoma</i> , 1996, 21, 311-316.	0.6	34
222	Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. <i>Leukemia</i> , 2014, 28, 1687-1697.	3.3	34
223	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 38.	6.9	34
224	Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. <i>Cancer Medicine</i> , 2016, 5, 2740-2755.	1.3	34
225	CD38, BCL2, PD1, and PD1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017, 92, E1-E2.	2.0	33
226	First Analysis of the Completed Mabthera International (Mint) Trial in Young Patients with Low-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Addition of Rituximab to a CHOP-Like Regimen Significantly Improves Outcome of All Patients with the Identification of a Very Favorable Subgroup with IPI=O and No Bulky Disease. <i>Blood</i> , 2004, 104, 157-157.	0.6	33
227	Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. <i>Haematologica</i> , 2002, 87, 816-21.	1.7	33
228	Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2000, 11, 363-366.	0.6	32
229	Primary Bone Lymphoma: Evaluation of Chemoimmunotherapy as Front-line Treatment in 21 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 321-325.	0.2	32
230	FDG PET/CT predictive role in follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 864-871.	3.3	32
231	<sc>SIE</sc>, <sc>SIES</sc>, <sc>GITMO</sc> revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 185-192.	2.0	32
232	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 75-85.	0.2	32
233	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. <i>Haematologica</i> , 2019, 104, e25-e28.	1.7	32
234	The many faces of marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 426-32.	0.9	32

#	ARTICLE	IF	CITATIONS
235	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 1662-73.	1.7	32
236	Safety and efficacy of ⁹⁰ Y-triumomab-tetritumomab-tixetan for untreated follicular lymphoma patients. An Italian cooperative study. <i>British Journal of Haematology</i> , 2014, 164, 710-716.	1.2	31
237	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 214-227.	2.0	31
238	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.4	31
239	Efficacy of Rituximab in Hairy Cell Leukemia Treatment. <i>Journal of Clinical Oncology</i> , 2000, 18, 3875-3877.	0.8	30
240	FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1995, 55, 262-266.	1.1	30
241	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	1.2	30
242	Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 359-369.	2.0	30
243	The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. <i>Hematological Oncology</i> , 2015, 33, 145-150.	0.8	30
244	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005, 90, 1236-57.	1.7	30
245	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 96-103.	1.7	30
246	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 228-240.	2.0	29
247	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020, 9, 6565-6575.	1.3	29
248	Phase III Comparative Trial Using CHOP vs CIOP in the Treatment of Advanced Intermediate-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 19, 329-335.	0.6	28
249	Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2002, 20, 638-646.	0.8	28
250	Fludarabine in patients with advanced and/or resistant B-cell chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 1993, 51, 93-97.	1.1	28
251	Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 715-718.	2.3	28
252	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.	6.9	28

#	ARTICLE	IF	CITATIONS
253	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	3.3	28
254	Monitoring Bulky Mediastinal Disease with Gallium-67, CT-Scan and Magnetic Resonance Imaging in Hodgkin's Disease and High-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 22, 131-135.	0.6	27
255	FLAG (Fludarabine, Cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: <i>in vitro</i> and <i>in vivo</i> effects. <i>European Journal of Haematology</i> , 1996, 56, 308-312.	1.1	27
256	A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. <i>Annals of Oncology</i> , 2012, 23, 415-420.	0.6	27
257	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. <i>Hematological Oncology</i> , 2013, 31, 183-188.	0.8	27
258	Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. <i>Cancer Treatment Reviews</i> , 2017, 61, 61-69.	3.4	27
259	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	1.3	27
260	2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. <i>European Journal of Haematology</i> , 1997, 58, 46-50.	1.1	26
261	FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. <i>Annals of Oncology</i> , 2010, 21, 1877-1883.	0.6	26
262	Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. <i>British Journal of Haematology</i> , 2016, 174, 692-699.	1.2	26
263	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 4457-4457.	0.6	26
264	Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop. <i>European Journal of Cancer</i> , 2008, 44, 366-373.	1.3	25
265	Prognostic Value of Interim Positron Emission Tomography in Patients With Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2014, 19, 746-750.	1.9	25
266	Treatment of hairy-cell leukaemia with α -interferon (α -IFN). <i>European Journal of Cancer & Clinical Oncology</i> , 1988, 24, 195-200.	0.9	24
267	The Role of Anthracyclines in Combination Chemotherapy for the Treatment of Follicular Lymphoma: Retrospective Study of the Intergruppo Italiano Linfomion 761 Cases. <i>Leukemia and Lymphoma</i> , 2003, 44, 1911-1917.	0.6	24
268	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 21-44.	2.0	24
269	GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. <i>BMC Cancer</i> , 2012, 12, 586.	1.1	24
270	Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. <i>Hematological Oncology</i> , 2013, 31, 223-224.	0.8	24

#	ARTICLE	IF	CITATIONS
271	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	2.8	24
272	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , 2020, 7, e649-e659.	2.2	24
273	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6124-6134.	3.2	24
274	¹⁸F-FDG PET Early After Radiotherapy in Lymphoma Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 606-612.	0.7	24
275	Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1224-1232.	2.0	23
276	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018, 59, 1814-1828.	0.6	23
277	PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment. <i>Blood</i> , 2015, 126, 584-584.	0.6	23
278	Consistency of FDG-PET Accuracy and Cost-Effectiveness in Initial Staging of Patients With Hodgkin Lymphoma Across Jurisdictions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 314-320.	0.2	22
279	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015, 56, 1671-1676.	0.6	22
280	Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. <i>Oncologist</i> , 2015, 20, 1413-1416.	1.9	22
281	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	1.3	22
282	Cryptococcal Meningitis and Intracranial Tuberculoma in a Patient with Waldenstrom's Macroglobulinemia Treated with Fludarabine. <i>Leukemia and Lymphoma</i> , 1998, 28, 617-620.	0.6	21
283	Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-Analysis of the Published Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 258-265.	0.2	21
284	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	1.3	21
285	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 3502-3502.	0.6	21
286	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	0.8	21
287	Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. <i>Annals of Oncology</i> , 2002, 13, 1364-1369.	0.6	20
288	Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2013, 54, 2318-2321.	0.6	20

#	ARTICLE	IF	CITATIONS
289	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013, 31, 179-182.	0.8	20
290	Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. <i>Haematologica</i> , 2016, 101, e385-e386.	1.7	20
291	Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 3552-3556.	3.2	20
292	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18â€‹FDG PET</sc>/<sc>CT</sc> quantitative parameters in the International Extranodal Lymphoma Study Group (<sc>IELSG</sc>) 26 study. <i>British Journal of Haematology</i> , 2017, 178, 588-591.	1.2	20
293	Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.. <i>Journal of Clinical Oncology</i> , 1996, 14, 3018-3025.	0.8	19
294	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002, 118, 218-228.	1.2	19
295	Bronchus-Associated Lymphoid Tissue Lymphomas: An Update of a Rare Extranodal Maltoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 566-572.	1.4	19
296	Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. <i>Rheumatology International</i> , 2012, 32, 2209-2213.	1.5	19
297	Bendamustine: role and evidence in lymphoma therapy, an overview. <i>Leukemia and Lymphoma</i> , 2014, 55, 1471-1478.	0.6	19
298	The role of transplantation in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 93-104.	1.2	19
299	Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. <i>Blood Advances</i> , 2021, 5, 823-828.	2.5	19
300	Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in lowâ€‹grade nonâ€‹Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1996, 57, 335-340.	1.1	18
301	Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1354-1360.	2.8	18
302	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 404-408.	0.2	18
303	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 12-25.	0.6	18
304	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 65-70.	2.0	18
305	NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL. <i>Hematological Oncology</i> , 2017, 35, 135-136.	0.8	18
306	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2020, 95, 1553-1561.	2.0	18

#	ARTICLE	IF	CITATIONS
307	Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. <i>Cancers</i> , 2021, 13, 4789.	1.7	18
308	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. <i>Cell Reports Medicine</i> , 2020, 1, 100158.	3.3	18
309	Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1218-1218.	0.6	18
310	Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype. <i>Cancer</i> , 1990, 65, 2233-2236.	2.0	17
311	Induction of "In Vitro" Apoptosis by Fludarabine in Freshly Isolated B-Chronic Lymphocytic Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1994, 13, 95-97.	0.6	17
312	T-cell prolymphocytic leukaemia: Does the expression of CD8+ phenotype justify the identification of a new subtype?. <i>Annals of Oncology</i> , 1999, 10, 649-653.	0.6	17
313	Diffuse large B-cell lymphoma with primary retroperitoneal presentation: Clinico-pathologic study of nine cases. <i>Annals of Oncology</i> , 2001, 12, 1445-1453.	0.6	17
314	Aggressive lymphoma: improving treatment outcome with rituximab. <i>Anti-Cancer Drugs</i> , 2002, 13, S43-S50.	0.7	17
315	Indolent lymphoma: the pathologist's viewpoint. <i>Annals of Oncology</i> , 2004, 15, 12-18.	0.6	17
316	Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 287-289.	0.2	17
317	Angioimmunoblastic T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 223-238.	0.9	17
318	Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E575-E583.	2.0	17
319	Effectiveness of chemotherapy after anti-CD20 blockade failure for relapsed and refractory Hodgkin lymphoma. <i>Cancer Medicine</i> , 2020, 9, 7830-7836.	1.3	17
320	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , 2021, 5, 3387-3396.	2.5	17
321	A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis. <i>Blood</i> , 2019, 134, 4078-4078.	0.6	17
322	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010, 116, 2462-2462.	0.6	17
323	First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962). <i>Blood</i> , 2015, 126, 341-341.	0.6	17
324	Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative) <i>TJ ETQq0 0 0 rgBTd/Overlork 10 Tf 50</i>		

#	ARTICLE	IF	CITATIONS
325	PI3K γ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. <i>Cancers</i> , 2021, 13, 5535.	1.7	17
326	Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. <i>Blood Advances</i> , 2022, 6, 5550-5555.	2.5	17
327	MACOP-B vs F-MACHOP Regimen in the Treatment of High-Grade Non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 1995, 16, 457-463.	0.6	16
328	Primary Gastric Lymphoma: A Clinical and Therapeutic Evaluation of 82 Patients. <i>Leukemia and Lymphoma</i> , 1995, 19, 461-466.	0.6	16
329	Cytotoxic Combination of Loxoribine with Fludarabine and Mafosfamide on Freshly Isolated B-Chronic Lymphocytic Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1999, 33, 147-153.	0.6	16
330	Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. <i>Lancet Oncology</i> , The, 2004, 5, 381-383.	5.1	16
331	Novel Therapies for Aggressive B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-22.	0.6	16
332	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. <i>Journal of Hematology and Oncology</i> , 2012, 5, 67.	6.9	16
333	Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib+Rituximab Versus Rituximab. <i>Clinical Cancer Research</i> , 2013, 19, 2551-2561.	3.2	16
334	⁹⁰ Yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7.5 years. <i>Cancer Medicine</i> , 2016, 5, 1093-1097.	1.3	16
335	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 628-634.	2.0	16
336	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2225-2238.	1.3	16
337	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). <i>Journal of Clinical Oncology</i> , 2014, 32, 8519-8519.	0.8	16
338	Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. <i>Haematologica</i> , 2005, 90, 1283-4.	1.7	16
339	Hodgkin's disease (HD): A historical perspective. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 1315-1323.	0.9	15
340	Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S6-S14.	0.6	15
341	Primary Mediastinal DLBCL: Evolving Biologic Understanding and Therapeutic Strategies. <i>Current Oncology Reports</i> , 2011, 13, 407-415.	1.8	15
342	SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. <i>Annals of Oncology</i> , 2014, 25, 2339-2350.	0.6	15

#	ARTICLE	IF	CITATIONS
343	Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. <i>Oncologist</i> , 2016, 21, 1436-1441.	1.9	15
344	Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2705-2711.	0.6	15
345	Nonpegylated liposomal doxorubicin combination regimen (<sc>RÊCOMP</sc>) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020, 38, 478-486.	0.8	15
346	Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2015, 126, 3986-3986.	0.6	15
347	Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8503-8503.	0.8	15
348	A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2010, 116, 2803-2803.	0.6	15
349	The inhibitory effect of serum from hairy-cell leukaemia patients on normal progenitor cells may disappear following prolonged treatment with \pm -interferon. <i>British Journal of Haematology</i> , 1989, 72, 497-501.	1.2	14
350	High Complete Remission Rate in Hairy Cell Leukemia Treated with 2-Chlorodeoxyadenosine. <i>Leukemia and Lymphoma</i> , 1993, 11, 399-404.	0.6	14
351	EXTEND PIX301: A Phase III Randomized Trial of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Monotherapy in Patients with Relapsed, Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 152-154.	1.4	14
352	Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. <i>Leukemia and Lymphoma</i> , 2009, 50, 481-484.	0.6	14
353	Immunophenotype and intermediateÊhigh international prognostic index score are prognostic factors for therapy in diffuse large BÊcell lymphoma patients. <i>Cancer</i> , 2010, 116, 5667-5675.	2.0	14
354	PET in T-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 241-244.	1.2	14
355	Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 493-495.	0.2	14
356	Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. <i>British Journal of Haematology</i> , 2013, 163, 681-683.	1.2	14
357	Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1585-1592.	3.3	14
358	Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. <i>Annals of Hematology</i> , 2014, 93, 1853-1857.	0.8	14
359	The unique biology and treatment of primary mediastinal B-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 241-250.	0.7	14
360	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. <i>Blood Advances</i> , 2021, 5, 4504-4514.	2.5	14

#	ARTICLE	IF	CITATIONS
361	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018, 132, 228-228.	0.6	14
362	Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge. <i>Leukemia and Lymphoma</i> , 2008, 49, 159-162.	0.6	13
363	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 789-795.	0.6	13
364	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. <i>Leukemia Research</i> , 2014, 38, 1269-1277.	0.4	13
365	High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. <i>BMC Cancer</i> , 2015, 15, 879.	1.1	13
366	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 507-513.	0.2	13
367	Fludarabine+Mitoxantrone+Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. <i>Hematological Oncology</i> , 2015, 33, 141-146.	0.8	13
368	Short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. <i>Blood Cancer Journal</i> , 2016, 6, e425-e425.	2.8	13
369	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 950-954.	0.6	13
370	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2931-2938.	0.6	13
371	How do we sequence therapy for marginal zone lymphomas?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 295-305.	0.9	13
372	Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	2.5	13
373	Serum Soluble Interleukin-2 Receptor Levels in Hairy Cell Leukemia: Correlation with Clinical and Hematological Parameters and with ±-Interferon Treatment. <i>Leukemia and Lymphoma</i> , 1992, 7, 103-107.	0.6	12
374	Non-Hodgkin's lymphoma: the evolving role of purine analogues. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 505-516.	0.7	12
375	Difficult Diagnostic and Therapeutic Cases. <i>Journal of Clinical Oncology</i> , 2004, 22, 953-954.	0.8	12
376	Results of a fludarabine induction and ±-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1997, 59, 82-88.	1.1	12
377	Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 258-261.	0.2	12
378	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 805-807.	0.6	12

#	ARTICLE	IF	CITATIONS
379	Brentuximab vedotin followed by ABVD + ¹⁷⁷ radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016, 101, e139-e141.	1.7	12
380	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. <i>BMC Cancer</i> , 2020, 20, 1088.	1.1	12
381	The importance of assessing blood tumour burden in cutaneous Tâ€cell lymphoma*. <i>British Journal of Dermatology</i> , 2021, 185, 19-25.	1.4	12
382	Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).. <i>Blood</i> , 2009, 114, 1675-1675.	0.6	12
383	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	0.8	12
384	Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 177-190.	1.2	12
385	Cusatuzumab for treatment of CD70â€positive relapsed or refractory cutaneous Tâ€cell lymphoma. <i>Cancer</i> , 2022, 128, 1004-1014.	2.0	12
386	Successful Pregnancies, Births, and Children Development Following Oocyte Cryostorage in Female Cancer Patients During 25 Years of Fertility Preservation. <i>Cancers</i> , 2022, 14, 1429.	1.7	12
387	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
388	Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, 123-5.	1.1	11
389	VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. <i>Leukemia and Lymphoma</i> , 2007, 48, 2167-2171.	0.6	11
390	Biology and treatment of follicular lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 533-547.	1.0	11
391	Possible novel agents in marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 149-157.	0.7	11
392	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	1.7	11
393	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	0.6	11
394	A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. <i>BMC Cancer</i> , 2018, 18, 645.	1.1	11
395	Survival in <sc>HIV</sc>â€infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. <i>HIV Medicine</i> , 2018, 19, 523-531.	1.0	11
396	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019, 81, 88-94.	0.4	11

#	ARTICLE	IF	CITATIONS
397	The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020, 99, 277-282.	0.8	11
398	Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. <i>Hematological Oncology</i> , 2020, 38, 487-492.	0.8	11
399	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2022, 36, 197-209.	3.3	11
400	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2020, 38, 8020-8020.	0.8	11
401	Adult Burkitt's Lymphoma: Clinical and Prognostic Evaluation of 20 Patients. <i>Leukemia and Lymphoma</i> , 1994, 14, 465-470.	0.6	10
402	Loxoribine Affects Fludarabine Activity on Freshly Isolated B-chronic Lymphocytic Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 343-348.	0.6	10
403	MACOP-B Regimen Followed by Involved-Field Radiation Therapy in Early-Stage Aggressive Non-Hodgkin's Lymphoma Patients: 14-Year Update Results. <i>Leukemia and Lymphoma</i> , 2001, 42, 989-995.	0.6	10
404	Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S115-S122.	0.6	10
405	Short Communication: 18F-FDG PET Early After Radiotherapy in Lymphoma Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 606-612.	0.7	10
406	CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. <i>Journal of Neuro-Oncology</i> , 2009, 95, 135-139.	1.4	10
407	Targeted molecular therapy in peripheral T-cell lymphomas. <i>Expert Review of Hematology</i> , 2011, 4, 551-562.	1.0	10
408	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014, 55, 988-998.	0.6	10
409	PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY. <i>Hematological Oncology</i> , 2017, 35, 136-137.	0.8	10
410	The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. <i>BMC Cancer</i> , 2017, 17, 276.	1.1	10
411	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624.	4.9	10
412	Lenalidomide in Pretreated Patients with Diffuse Large B-cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	1.9	10
413	Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. <i>European Journal of Haematology</i> , 2021, 106, 737-739.	1.1	10
414	The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience. <i>American Journal of Hematology</i> , 2021, 96, 1204-1210.	2.0	10

#	ARTICLE	IF	CITATIONS
415	Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. <i>Blood</i> , 2018, 132, 2932-2932.	0.6	10
416	PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2008, 112, 261-261.	0.6	10
417	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014, 124, 1708-1708.	0.6	10
418	Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017, 130, 650-650.	0.6	10
419	Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 590-599.	2.5	10
420	FLAG (fludarabine + cytosine arabinoside + G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. <i>British Journal of Haematology</i> , 1994, 86, 394-396.	1.2	9
421	Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. <i>Bone Marrow Transplantation</i> , 2011, 46, 901-903.	1.3	9
422	Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1695-1701.	2.0	9
423	Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: Experience on 142 patients. <i>American Journal of Hematology</i> , 2013, 88, E273-6.	2.0	9
424	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. <i>European Journal of Haematology</i> , 2016, 97, 554-561.	1.1	9
425	Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT registry. <i>British Journal of Haematology</i> , 2019, 184, 949-956.	1.2	9
426	Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. <i>European Journal of Haematology</i> , 2020, 104, 499-508.	1.1	9
427	Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial. <i>Leukemia and Lymphoma</i> , 2021, 62, 3109-3118.	0.6	9
428	A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8615-TPS8615.	0.8	9
429	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204). <i>Blood</i> , 2020, 136, 27-28.	0.6	9
430	Lymphoblastic lymphoma in adolescents and adults. Clinical, pathological and prognostic evaluation. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 1503-1510.	0.9	8
431	Flang (Fludarabine + Cytosine Arabinoside + Novantrone + G-CSF) Induces Partial Remission in Lymphoid Blast Transformation of Ph ⁺ Chronic Myelogenous Leukaemia. <i>Leukemia and Lymphoma</i> , 1996, 22, 173-176.	0.6	8
432	ABVD and Radiation Therapy as First-Line Treatment in Advanced Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 1999, 32, 553-559.	0.6	8

#	ARTICLE	IF	CITATIONS
433	Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1437-1440.	0.6	8
434	Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. <i>British Journal of Haematology</i> , 2006, 134, 356-356.	1.2	8
435	Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. <i>Nuclear Medicine Communications</i> , 2008, 29, 705-710.	0.5	8
436	Long-term follow-up studies in hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 23-26.	0.6	8
437	Persistent Agmination of Lymphomatoid Papulosis: An Ongoing Debate. <i>Dermatology</i> , 2012, 225, 131-134.	0.9	8
438	Leukocytoclastic Vasculitis Associated with Hairy Cell Leukemia at Diagnosis: A Case Report and Review of the Literature. <i>Tumori</i> , 2016, 102, S124-S127.	0.6	8
439	Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and SÅ©zary syndrome?. <i>European Journal of Dermatology</i> , 2017, 27, 49-53.	0.3	8
440	Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. <i>Leukemia and Lymphoma</i> , 2018, 59, 2990-2993.	0.6	8
441	Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e595-e596.	0.2	8
442	Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1661-1671.	3.3	8
443	A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKB1A</i> improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.	1.7	8
444	Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3058-3065.	3.3	8
445	Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e886-e894.	0.2	8
446	Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. <i>Hematological Oncology</i> , 2022, 40, 58-63.	0.8	8
447	Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.. <i>Blood</i> , 2009, 114, 2699-2699.	0.6	8
448	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	8
449	High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1986, 37, 347-352.	1.1	7
450	Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, S27-S31.	2.0	7

#	ARTICLE	IF	CITATIONS
451	Rituximab in Heavily Pretreated Cutaneous B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 1637-1638.	0.6	7
452	Challenging paradigms in lymphoma treatment. <i>Annals of Oncology</i> , 2004, 15, 703-711.	0.6	7
453	Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 1815-1819.	0.6	7
454	Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 1449-1454.	0.6	7
455	Posttransplant Lymphoproliferative Disorders in Liver Transplanted Patients: A Report of Four Cases. <i>Transplantation Proceedings</i> , 2006, 38, 1477-1480.	0.3	7
456	Role of interferon-alpha administration after 2-deoxycytosine in the treatment of hairy cell leukemia patients. <i>European Journal of Haematology</i> , 2006, 77, 109-113.	1.1	7
457	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 459-466.	0.4	7
458	Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1261-1275.	0.9	7
459	The emerging role of GSK-3 β in the pathobiology of classical Hodgkin lymphoma. <i>Histopathology</i> , 2017, 71, 72-80.	1.6	7
460	Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2017, 137, 191-194.	0.7	7
461	Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. <i>Immunotherapy</i> , 2018, 10, 699-711.	1.0	7
462	Cutaneous adverse events in patients treated with Ibrutinib. <i>Dermatologic Therapy</i> , 2020, 33, e14190.	0.8	7
463	Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience. <i>Hematological Oncology</i> , 2020, 38, 737-741.	0.8	7
464	Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).. <i>Blood</i> , 2009, 114, 1676-1676.	0.6	7
465	Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 1528-1528.	0.6	7
466	Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma. <i>Blood</i> , 2015, 126, 3935-3935.	0.6	7
467	Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab. <i>Journal of Translational Medicine</i> , 2021, 19, 489.	1.8	7
468	Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 5845.	1.0	7

#	ARTICLE	IF	CITATIONS
469	A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. <i>Blood Advances</i> , 2022, 6, 4224-4227.	2.5	7
470	Massive Mediastinal Involvement in Stage I-II Hodgkin's Disease: Response to Combined Modality Treatment. <i>Leukemia and Lymphoma</i> , 1992, 8, 81-85.	0.6	6
471	Cep Regimen (Cenu, Etoposide, Prednimustine) for Relapsed/Refractory Hodgkin's Disease. <i>Tumori</i> , 1994, 80, 438-442.	0.6	6
472	Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. <i>Annals of Oncology</i> , 2001, 12, 1479-1484.	0.6	6
473	Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2004, 5, S38-S49.	2.0	6
474	Histopathology of B-cell chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 807-826.	0.9	6
475	Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 115-124.	1.4	6
476	B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. <i>Journal of Clinical Pathology</i> , 2007, 60, 627-632.	1.0	6
477	Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. <i>Annals of Nuclear Medicine</i> , 2008, 22, 429-432.	1.2	6
478	Vemurafenib mucosal side effect. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1053-1055.	1.3	6
479	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. <i>Leukemia and Lymphoma</i> , 2017, 58, 226-229.	0.6	6
480	Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant. <i>Hematological Oncology</i> , 2018, 36, 489-491.	0.8	6
481	Consolidation with ⁹⁰ Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. <i>Leukemia and Lymphoma</i> , 2019, 60, 2689-2696.	0.6	6
482	EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. <i>Hematological Oncology</i> , 2019, 37, 387-389.	0.8	6
483	New therapies and old side effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. <i>British Journal of Dermatology</i> , 2019, 180, 1535-1536.	1.4	6
484	⁹⁰ Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) – The Zeno Study. <i>British Journal of Haematology</i> , 2020, 189, e6-e9.	1.2	6
485	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	0.6	6
486	ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8616-TPS8616.	0.8	6

#	ARTICLE	IF	CITATIONS
487	Utility of surgical resection with or without radiation therapy in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Haematologica</i> , 2003, 88, 830-1.	1.7	6
488	Continuous infusion of interleukin-2 in two relapsed high grade non-Hodgkin lymphoma patients: Effectiveness and tolerability. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 521-522.	0.9	5
489	Anthracycline Containing Regimens in Intermediate Grade Lymphoma. <i>Leukemia and Lymphoma</i> , 1993, 10, 39-41.	0.6	5
490	2-Chlorodeoxyadenosine in psoriasis treatment. <i>Annals of Oncology</i> , 1995, 6, 509.	0.6	5
491	Factor VIII Inhibitor Prior to and During Secondary Acute Nonlymphocytic Leukemia in a Patient with Cured Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 1995, 16, 511-513.	0.6	5
492	Bilateral Primary Breast Lymphoma: A Case of Local Recurrence. <i>Leukemia and Lymphoma</i> , 2003, 44, 737-738.	0.6	5
493	High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience. <i>Leukemia and Lymphoma</i> , 2004, 45, 321-326.	0.6	5
494	Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin's Lymphomas. <i>Acta Haematologica</i> , 2005, 114, 255-259.	0.7	5
495	Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2005, 46, 1839-1841.	0.6	5
496	Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1048-1052.	0.6	5
497	Results in hairy cell leukemia patients treated with interferon: Predictive prognostic factors. <i>European Journal of Haematology</i> , 1992, 49, 133-137.	1.1	5
498	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1824-1829.	0.6	5
499	Consensus conference on the use of 90Yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. <i>American Journal of Hematology</i> , 2010, 85, 147-155.	2.0	5
500	Is it really possible to cure hairy cell leukemia patients only with frontline therapy?. <i>Annals of Hematology</i> , 2014, 93, 1565-1569.	0.8	5
501	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	0.6	5
502	Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e373-e376.	1.3	5
503	Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. <i>Hematological Oncology</i> , 2018, 36, 689-692.	0.8	5
504	PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series. <i>Haematologica</i> , 2019, 104, e521-e522.	1.7	5

#	ARTICLE	IF	CITATIONS
505	PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND). <i>Hematological Oncology</i> , 2019, 37, 173-174.	0.8	5
506	Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. <i>Annals of Hematology</i> , 2020, 99, 283-291.	0.8	5
507	Controversies in the Treatment of Peripheral Tâ€cell Lymphoma. <i>HemaSphere</i> , 2020, 4, e461.	1.2	5
508	Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. <i>Annals of Hematology</i> , 2020, 99, 1073-1079.	0.8	5
509	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large Bâ€cell lymphoma in the phase III clinical trial of Râ€CHOPâ€Â±Âibrutinib. <i>British Journal of Haematology</i> , 2021, 194, 83-91.	1.2	5
510	Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 by the Italian Cooperative Group on Hcl. <i>Blood</i> , 2010, 116, 701-701.	0.6	5
511	A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. <i>Blood</i> , 2010, 116, 857-857.	0.6	5
512	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. <i>Blood</i> , 2015, 126, 2018-2018.	0.6	5
513	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8507-8507.	0.8	5
514	ITF2357, a Novel Histone-Deacetylase Inhibitor, Is Effective against Peripheral T-Cell Lymphomas in Vivo. <i>Blood</i> , 2008, 112, 4981-4981.	0.6	5
515	Collection of Hematopoietic Stem Cells After Previous Exposure to Itrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.. <i>Blood</i> , 2012, 120, 3019-3019.	0.6	5
516	The role of surgery for haematologic neoplasms of bone. <i>Acta Orthopaedica Belgica</i> , 2012, 78, 382-92.	0.1	5
517	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. <i>Frontiers in Oncology</i> , 2021, 11, 789891.	1.3	5
518	Ceop Regimen in the Treatment of Advanced Low-Grade Non-Hodgkin's Lymphomas: Preliminary Report. <i>Tumori</i> , 1990, 76, 533-536.	0.6	4
519	Comparison of Low-Dose versus Standard-Dose Alpha-Interferon Regimen in the Hairy Cell Leukemia Treatment. <i>Acta Haematologica</i> , 1991, 85, 16-19.	0.7	4
520	Radiotherapy in Early Stage Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 1994, 13, 285-289.	0.6	4
521	High-Dose Therapy and Stem Cell Transplantation. <i>Seminars in Hematology</i> , 2010, 47, S15-S17.	1.8	4
522	Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e119-e122.	0.2	4

#	ARTICLE	IF	CITATIONS
523	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 24.	2.0	4
524	ALCL: is it now a curable disease?. <i>Blood</i> , 2017, 130, 2691-2692.	0.6	4
525	Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis. <i>Hematological Oncology</i> , 2018, 36, 136-143.	0.8	4
526	<p>BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4807-4812.	1.0	4
527	Spontaneous remission of follicular lymphoma. <i>Hematological Oncology</i> , 2019, 37, 626-627.	0.8	4
528	Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2247-2254.	0.6	4
529	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1204-1213.	0.6	4
530	Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. <i>Annals of Hematology</i> , 2021, 100, 2261-2268.	0.8	4
531	Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 933-937.	0.2	4
532	Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry. <i>Acta Haematologica</i> , 2021, 144, 259-263.	0.7	4
533	Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma. <i>Hematological Oncology</i> , 2021, 39, 275-283.	0.8	4
534	Phase II Study of Alemtuzumab Treatment in Patients with Pretreated T-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 4605-4605.	0.6	4
535	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2006, 108, 2479-2479.	0.6	4
536	IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease. <i>Blood</i> , 2010, 116, 3890-3890.	0.6	4
537	Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012, 120, 903-903.	0.6	4
538	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014, 124, 150-150.	0.6	4
539	A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2014, 124, 1763-1763.	0.6	4
540	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4

#	ARTICLE	IF	CITATIONS
541	Thoughts on the eradication of <i>Helicobacter pylori</i> infection in localized gastric mucosa-associated lymphoid tissue lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2013-2014.	0.6	3
542	Critical value of laparotomy with splenectomy in Stage III Hodgkin's disease as restaging procedure after chemotherapy. <i>European Journal of Haematology</i> , 1988, 41, 6-11.	1.1	3
543	Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, Tj ETQq1 1 0.784314 rgBT /Overlock autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 625-628.	1.2	3
544	Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1969-1974.	0.6	3
545	Reporting real-life experience with drugs in lymphoma patients. <i>Hematological Oncology</i> , 2017, 35, 909-910.	0.8	3
546	Efficacy of Idelalisib as Bridge to Allogeneic Stem Cell Transplant in Relapsed Follicular Lymphoma: A Case Report. <i>Tumori</i> , 2017, 103, S41-S43.	0.6	3
547	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038.	1.9	3
548	Phosphatidylinositol 3-kinase inhibitors in the treatment of T-cell lymphomas. <i>Annals of Lymphoma</i> , 0, 1, 1-1.	4.5	3
549	Plaques and tumors in a patient with refractory SÅ©zary syndrome treated with mogamulizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1263-1265.	0.4	3
550	Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. <i>International Reviews of Immunology</i> , 2019, 38, 79-91.	1.5	3
551	Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1007-1009.	0.6	3
552	Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.. <i>Blood</i> , 2009, 114, 1662-1662.	0.6	3
553	Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study. <i>Blood</i> , 2011, 118, 265-265.	0.6	3
554	Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma. <i>Blood</i> , 2011, 118, 2727-2727.	0.6	3
555	The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP.. <i>Blood</i> , 2012, 120, 2721-2721.	0.6	3
556	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 850-850.	0.6	3
557	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. <i>Blood</i> , 2014, 124, 3088-3088.	0.6	3
558	Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study. <i>Blood</i> , 2015, 126, 1541-1541.	0.6	3

#	ARTICLE	IF	CITATIONS
559	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. <i>Blood</i> , 2015, 126, 3946-3946.	0.6	3
560	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	0.6	3
561	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19554-e19554.	0.8	3
562	Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukemia patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 605-606.	0.8	3
563	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Follidela Study. <i>Cancers</i> , 2022, 14, 654.	1.7	3
564	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
565	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
566	Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas. <i>Blut</i> , 1990, 60, 172-176.	1.2	2
567	Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience. <i>Annals of Oncology</i> , 2003, 14, i43-i45.	0.6	2
568	Primary gastric diffuse large-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1201-1202.	0.6	2
569	T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2009, 31, .	0.7	2
570	CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. <i>Journal of Clinical Pathology</i> , 2011, 64, 83-87.	1.0	2
571	A treatment for activated B-cell-like DLBCL?. <i>Lancet Oncology</i> , The, 2014, 15, 916-917.	5.1	2
572	Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis. <i>Hematological Oncology</i> , 2015, 33, 164-165.	0.8	2
573	An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013. , 2015, 3, .		2
574	PET/CT-GUIDED BIOPSY FOR THE DIAGNOSIS OF LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 425-425.	0.8	2
575	Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e15-e17.	0.2	2
576	Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 99-102.	0.4	2

#	ARTICLE	IF	CITATIONS
577	Lymph node core needle biopsy in lymphoproliferative disordersâ€™ Authorsâ€™™ reply to Alâ€™Abbadi and colleagues. <i>European Journal of Haematology</i> , 2021, 107, 297-298.	1.1	2
578	Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 1659-1659.	0.6	2
579	The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi.. <i>Blood</i> , 2009, 114, 3758-3758.	0.6	2
580	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Blood</i> , 2012, 120, 1566-1566.	0.6	2
581	Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection. <i>Blood</i> , 2012, 120, 3694-3694.	0.6	2
582	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 3047-3047.	0.6	2
583	Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2014, 124, 1755-1755.	0.6	2
584	Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat. <i>Blood</i> , 2014, 124, 3075-3075.	0.6	2
585	The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BR106 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 2735-2735.	0.6	2
586	How do we define Hodgkin's disease? The authors' reply. <i>Journal of Clinical Pathology</i> , 2003, 56, 159-159.	1.0	1
587	Prolonged bone marrow aplasia of refractory porolymphocytoid variant of Bâ€™cell chronic lymphocytic leukemia related to fludarabine treatment. <i>European Journal of Haematology</i> , 1994, 53, 56-58.	1.1	1
588	Late FDG PET Normalization After Radioimmunotherapy in a Patient With Non-Hodgkin Lymphoma. <i>Clinical Nuclear Medicine</i> , 2009, 34, 777-778.	0.7	1
589	499 Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. <i>European Journal of Cancer</i> , 2014, 50, 162-163.	1.3	1
590	Erythematous induration of the chest. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1291-1293.	0.4	1
591	Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2016, 34, 49-51.	0.8	1
592	L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY. <i>Hematological Oncology</i> , 2017, 35, 51-52.	0.8	1
593	Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: AÂ³Thirty-year Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 297-299.	0.2	1
594	Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report. <i>Journal of Cancer Science & Therapy</i> , 2018, 10, .	1.7	1

#	ARTICLE	IF	CITATIONS
595	New Treatment Options in Advanced Stage Follicular Lymphoma. HemaSphere, 2018, 2, e156.	1.2	1
596	Plaques und Tumoren unter der Therapie mit Mogamulizumab bei einer Patientin mit refraktärem SÄ©zary-Syndrom. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1263-1266.	0.4	1
597	The Berlinâ€Frankfurtâ€MÃ¼nster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience. American Journal of Hematology, 2018, 93, E209.	2.0	1
598	NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY. Hematological Oncology, 2019, 37, 157-158.	0.8	1
599	A case report of the long treatment experience of a SÄ©zary syndrome responder patient: 16 years through all the systemic and innovative therapies. Hematological Oncology, 2019, 37, 202-204.	0.8	1
600	Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. Acta Haematologica, 2020, 143, 594-597.	0.7	1
601	Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report. European Journal of Haematology, 2020, 105, 505-507.	1.1	1
602	Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding. Tumori, 2020, 106, NP29-NP32.	0.6	1
603	Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?. Current Hematologic Malignancy Reports, 2021, 16, 82-88.	1.2	1
604	Phase I, first-in-human trial of Brutonâ€™s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. Leukemia and Lymphoma, 2021, 62, 1-8.	0.6	1
605	Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report. Tumori, 2021, 107, NP105-NP107.	0.6	1
606	Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases. Leukemia and Lymphoma, 2021, 62, 3540-3543.	0.6	1
607	Primary Mediastinal Large B-Cell Lymphoma: Investigation On The Role Of Rituximab and PET During Treatment. Blood, 2013, 122, 3046-3046.	0.6	1
608	A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.. Journal of Clinical Oncology, 2014, 32, TPS3116-TPS3116.	0.8	1
609	Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report. Acta Haematologica, 2021, , 1-3.	0.7	1
610	Report of a Phase II Study of Proteasome Inhibitor Bortezomib (Velcade) in Patients with Relapsed or Refractory T-Cell Lymphoma.. Blood, 2005, 106, 4764-4764.	0.6	1
611	Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network. Blood, 2008, 112, 3064-3064.	0.6	1
612	The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 2732-2732.	0.6	1

#	ARTICLE	IF	CITATIONS
613	The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma. <i>Blood</i> , 2011, 118, 2731-2731.	0.6	1
614	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. <i>Blood</i> , 2015, 126, 3937-3937.	0.6	1
615	Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2015, 126, 2725-2725.	0.6	1
616	Lymphoma and Myeloma of the Sacrum. , 2017, , 227-235.		1
617	Granulomatous tattoo reaction in a nivolumab-treated patient. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 530-532.	0.8	1
618	Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral Tâ€cell lymphoma: A FIL phase 2 study. <i>Hematological Oncology</i> , 2022, 40, 307-309.	0.8	1
619	BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	1
620	The safety and clinical effectiveness of rapid infusion with CTâ€P10 in patients with nonâ€Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective nonâ€interventional postâ€authorization safety study in Europe. <i>Hematological Oncology</i> , 2022, , .	0.8	1
621	Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series. <i>Tumori</i> , 2022, , 030089162210903.	0.6	1
622	Anthracycline Containing Regimens in Intermediate Grade Lymphoma. <i>Leukemia and Lymphoma</i> , 1992, 7, 22-24.	0.6	0
623	High-dose therapy followed by autologous bone marrow transplantation in previously untreated high grade non-Hodgkin's lymphoma: 10-year long-term results. <i>European Journal of Cancer</i> , 1995, 31, 2421-2422.	1.3	0
624	Waldenstromâ€™s macroglobulinemia: is there a place and time for a cease-fire?. <i>Leukemia Research</i> , 2003, 27, 465-466.	0.4	0
625	The First International Workshop on Non-Hodgkin's Lymphoma: Taking a Close Look at Current Issues and Future Developments. <i>Leukemia and Lymphoma</i> , 2003, 44, S1-S4.	0.6	0
626	Lymphoproliferative Lung Disorders. , 2007, 36, 307-322.		0
627	Local Versus Systemic Treatment for Primary Cutaneous B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S103-S105.	0.2	0
628	14 Recent progress in the treatment for T-cell malignancies. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 9.	2.2	0
629	PSY22 ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL). <i>Value in Health</i> , 2011, 14, A63.	0.1	0
630	Primary ocular adnexal lymphomas: a retrospective study of 25 patients. <i>Leukemia and Lymphoma</i> , 2013, 54, 2076-2078.	0.6	0

#	ARTICLE	IF	CITATIONS
631	Peripheral T-cell lymphomas: in "real life" experience are we really improving?. <i>Leukemia and Lymphoma</i> , 2013, 54, 2337-2338.	0.6	0
632	Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. <i>Leukemia and Lymphoma</i> , 2013, 54, 1791-1793.	0.6	0
633	Reactive follicular lymphoid infiltrate: A new condition to exclude in patients with PET positivity inside the heart. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 402-405.	1.4	0
634	Past, present and future treatment strategies in peripheral T-cell lymphomas. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 299-311.	0.7	0
635	Erythematöse Induration im Brustbereich. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1291-1293.	0.4	0
636	Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r) Tj ETQq0 0 0 rgBT /Overlock 10 Tt		
637	PET in natural killer/T-cell lymphoma: the debate continues. <i>Lancet Haematology</i> , 2015, 2, e50-e51.	2.2	0
638	Benda-BEAM High-Dose Therapy Prior to Auto-SCT is Effective in Resistant/Relapsed DLBCL. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S38.	2.0	0
639	Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma " Authors' reply. <i>Lancet Haematology</i> , 2017, 4, e64-e66.	2.2	0
640	PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL). <i>Hematological Oncology</i> , 2017, 35, 53-53.	0.8	0
641	Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice. <i>Hematological Oncology</i> , 2017, 35, 918-920.	0.8	0
642	RALE051: a novel established cell line of sporadic Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1252-1255.	0.6	0
643	Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review. <i>Bariatric Surgical Patient Care</i> , 2018, 13, 90-93.	0.1	0
644	PHASE 1B KEYNOTE-013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW-UP. <i>Hematological Oncology</i> , 2019, 37, 296-298.	0.8	0
645	A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 554-555.	0.8	0
646	SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 389-390.	0.8	0
647	COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 399-400.	0.8	0
648	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e321-e323.	0.2	0

#	ARTICLE	IF	CITATIONS
649	CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL. <i>Hematological Oncology</i> , 2019, 37, 140-142.	0.8	0
650	Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas. <i>Bone Marrow Transplantation</i> , 2021, 56, 2295-2298.	1.3	0
651	New Agents in Marginal Zone Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S61-S62.	0.2	0
652	A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.. <i>Blood</i> , 2006, 108, 2478-2478.	0.6	0
653	Lung lymphoma. , 2008, , 183-195.		0
654	Aberrant PDGFRA Signalling Is Sustained by An Autocrine Loop in Peripheral T-Cell Lymphoma Not Otherwise Specified. <i>Blood</i> , 2008, 112, 5331-5331.	0.6	0
655	PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2010, 116, 1770-1770.	0.6	0
656	The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011, 118, 2651-2651.	0.6	0
657	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011, 118, 2636-2636.	0.6	0
658	Abstract 4694: The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma. , 2012, , .		0
659	Effect of a combination of epigenetic agents on the malignant phenotype in models of T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13569-e13569.	0.8	0
660	Nucleoside Analogs in the Therapy of T-Cell Malignancies. , 2013, , 263-278.		0
661	Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.. <i>Blood</i> , 2012, 120, 2736-2736.	0.6	0
662	Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2013, 122, 3015-3015.	0.6	0
663	Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma. <i>Blood</i> , 2013, 122, 5543-5543.	0.6	0
664	Anaplastic Large Cell Lymphoma. , 2014, , 111-120.		0
665	Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications. <i>Blood</i> , 1997, 89, 1838-1839.	0.6	0
666	Abstract LB-105:In vitroandin vivosingle-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
667	Bendamustine in Combination with Rituximab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients: An Italian Retrospective Multicentre Study. Blood, 2014, 124, 1985-1985.	0.6	0
668	Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients. Blood, 2014, 124, 5458-5458.	0.6	0
669	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	0.6	0
670	The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients. Blood, 2014, 124, 4440-4440.	0.6	0
671	Efficacy and Safety of Biosimilar Epoetin Alpha in Patients with Chronic Lymphoproliferative Syndromes and Chemotherapy-Induced Anemia: An Observational, Retrospective, Monocentric Analysis. Blood, 2014, 124, 5478-5478.	0.6	0
672	Abstract CT221: CHRONOS-3: A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of phosphatidylinositol-3 kinase (PI3K) alpha/delta inhibitor copanlisib in combination with rituximab in patients with relapsed indolent B-c. , 2015, , .		0
673	Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma. Blood, 2015, 126, 2677-2677.	0.6	0
674	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. Blood, 2015, 126, 5009-5009.	0.6	0
675	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. Blood, 2016, 128, 4161-4161.	0.6	0
676	Standard of Care in T-Cell Lymphoma. Essentials, 2019, , 227-244.	0.1	0
677	The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna. Blood, 2019, 134, 4005-4005.	0.6	0
678	Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma. Tumori, 2020, 106, NP5-NP8.	0.6	0
679	Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation. Chemotherapy, 2022, , .	0.8	0